Abstract

Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101017549.

© GenoMed4All. All rights reserved